The Latest Immunotherapy Industry Statistics Explained
The market is expected to grow at a CAGR of 11.51% from 2020 to 2025.
The statistic “The market is expected to grow at a CAGR of 11.51% from 2020 to 2025” indicates that the market is projected to increase in size at a Compound Annual Growth Rate (CAGR) of 11.51% over the five-year period from 2020 to 2025. CAGR is a measure used to understand the annualized rate of growth of an investment or market, smoothing out the effects of volatility and providing a more consistent growth rate over time. In this context, the CAGR of 11.51% suggests a strong growth trajectory for the market, reflecting positive expectations for its expansion and potential opportunities for investors and stakeholders within the industry.
North America dominates the global immunotherapy drug market with a 45% share.
The statistic that North America dominates the global immunotherapy drug market with a 45% share indicates that North America, including the United States and Canada, holds a significant portion of the market for immunotherapy drugs compared to other regions worldwide. This suggests that a large proportion of immunotherapy drug sales, research, and development activities are concentrated in North America. Factors contributing to this dominance may include a strong healthcare infrastructure, advanced research capabilities, favorable regulatory environment, and high demand for innovative cancer treatments in the region. This statistic highlights North America’s leadership in the field of immunotherapy and its importance in driving advancements in cancer treatment globally.
Monoclonal antibodies dominated the global market and acquired a share of 77.4% in 2018.
This statistic indicates that monoclonal antibodies were the most widely used type of biopharmaceutical product in the global market in 2018, capturing a significant market share of 77.4%. Monoclonal antibodies are a type of protein-based therapy designed to target specific molecules in the body, making them valuable for treating various diseases such as cancer, autoimmune disorders, and infectious diseases. The dominance of monoclonal antibodies in the market suggests their widespread acceptance and utilization by healthcare providers and patients due to their efficacy and safety profiles. This statistic highlights the growing importance and impact of monoclonal antibodies in the field of biopharmaceuticals.
The immuno-oncology antibodies segment is expected to grow at a CAGR of 10.6% from 2019 to 2026.
The statistic indicates that the market for immuno-oncology antibodies, a type of cancer treatment that harnesses the body’s immune system to fight cancer cells, is projected to experience robust growth over the forecast period. The Compound Annual Growth Rate (CAGR) of 10.6% from 2019 to 2026 signals a steady and strong expansion in the demand for immuno-oncology antibodies, driven by factors such as advancements in biotechnology, increasing prevalence of cancer, and growing adoption of immunotherapy treatments. This growth rate suggests that the immuno-oncology antibodies segment is expected to outpace the overall pharmaceutical market growth, highlighting the significance and potential of these innovative therapies in the field of oncology.
In 2018, the infectious disease segment held an 18.4% share in the world immunotherapy drugs market.
The statistic ‘In 2018, the infectious disease segment held an 18.4% share in the world immunotherapy drugs market’ indicates that within the overall market for immunotherapy drugs across the globe in 2018, the portion attributed to treating infectious diseases specifically accounted for 18.4%. This suggests that a significant portion of the market was dedicated to developing and selling immunotherapy drugs targeted at combating infectious diseases, such as viral or bacterial infections. Understanding this statistic is important for stakeholders in the pharmaceutical and healthcare industries, as it highlights the specific focus and importance of addressing infectious diseases within the broader landscape of immunotherapy drug development and usage.
The vaccines segment is expected to be the fastest-growing segment in the immunotherapy market with a CAGR of 11.2% from 2018 to 2026.
This statistic indicates that the vaccines segment within the immunotherapy market is projected to experience significant growth over the period from 2018 to 2026. The Compounded Annual Growth Rate (CAGR) of 11.2% suggests a consistent and robust expansion in this particular segment. This growth rate outpaces the expected growth rates of other segments within the immunotherapy market. The increasing demand for vaccines as a preventive measure against various diseases, coupled with advancements in vaccine technology and research, are likely driving factors behind this anticipated growth. This trend highlights the potential importance of vaccines in the overall landscape of immunotherapy and underscores their crucial role in disease prevention and treatment.
As per the reports, over 3,400 immunotherapy agents were in development stage in 2019.
The statistic that over 3,400 immunotherapy agents were in the development stage in 2019 indicates a significant level of investment and focus on advancing treatments for various diseases through immunotherapy. Immunotherapy is a rapidly growing field in the medical and pharmaceutical industries due to its potential for more personalized and effective approaches to treating conditions such as cancer, autoimmune diseases, and allergies. The large number of agents in development underscores the industry’s commitment to innovation and highlights the continuous efforts to enhance and expand treatment options for patients in need of new and improved therapies. This statistic illustrates the dynamic landscape of immunotherapy research and development in 2019, with the potential to bring about groundbreaking advancements in healthcare in the near future.
The Chinese immunotherapy market is expected to witness a CAGR of 20.3% between 2021-2026.
The statistic indicates that the Chinese immunotherapy market is projected to experience a Compound Annual Growth Rate (CAGR) of 20.3% from 2021 to 2026. This suggests a substantial and consistent growth trend in the market over the specified period. A CAGR of 20.3% indicates a significant increase in the market size and demand for immunotherapy products and services in China. Factors such as increasing awareness, advancements in technology, and rising investments in healthcare are likely driving this growth. This statistic highlights the potential opportunities for investors, healthcare providers, and pharmaceutical companies operating in the Chinese immunotherapy sector.
The market of immunotherapy in cancer treatment is expected to reach $27 billion by 2023.
The statistic that the market of immunotherapy in cancer treatment is projected to reach $27 billion by 2023 indicates a significant growth and investment in this innovative and promising approach to treating cancer. Immunotherapy harnesses the body’s own immune system to target and destroy cancer cells, offering potential for more effective and targeted treatments with fewer side effects compared to traditional therapies. The projected market size reflects both the increasing demand for new and improved cancer treatments and the industry’s recognition of the potential of immunotherapy to transform cancer care. This statistic underscores the growing importance and investment in immunotherapy as a key area of research and development within the field of oncology.
PD-1/PD-L1 inhibitors dominated the cancer immunotherapy market and accounted for 54% of the global shares.
This statistic indicates that PD-1/PD-L1 inhibitors, which are a type of cancer immunotherapy treatment that target specific proteins to boost the body’s immune response against cancer cells, have had a significant impact on the global market. Specifically, they accounted for a majority share of 54% in the overall market for cancer immunotherapy treatments. This dominance suggests that PD-1/PD-L1 inhibitors are widely recognized and adopted by healthcare providers and patients as effective options for managing and treating cancer. Their high market share also reflects the growing importance and success of immunotherapy in the field of oncology, signaling a shift towards more targeted and personalized approaches to cancer treatment.
The immunotherapy drugs market in Europe is expected to grow at a CAGR of 14% from 2019 to 2025.
This statistic indicates that the market for immunotherapy drugs in Europe is projected to experience significant growth over the period from 2019 to 2025, with a Compound Annual Growth Rate (CAGR) of 14%. This suggests a sustained and relatively rapid rate of expansion in the market for immunotherapy drugs throughout the forecasted period. Factors such as increasing investment in research and development, rising prevalence of chronic diseases, and advancements in technology and healthcare infrastructure are likely to drive this growth. The forecasted CAGR of 14% indicates a strong positive trend in the market, making it an attractive sector for pharmaceutical companies and investors looking to capitalize on the opportunities presented by the growing demand for immunotherapy drugs in Europe.
The global cancer immunotherapy market size was valued at $57.92 billion in 2020, and is estimated to reach $115.39 billion by 2028.
The statistic indicates that the global cancer immunotherapy market experienced significant growth in 2020, with a value of $57.92 billion. The projection suggests a continued upward trend, estimating that the market will more than double in size to reach $115.39 billion by 2028. This growth is likely driven by increasing investments in research and development, advancements in immunotherapy treatments, and the rising prevalence of cancer worldwide. The expanding market reflects the growing recognition and adoption of immunotherapy as a promising approach in the fight against cancer, indicating a positive outlook for the industry in the coming years.
References
0. – https://www.www.marketresearchfuture.com
1. – https://www.www.globenewswire.com
2. – https://www.www.360marketupdates.com
3. – https://www.www.marketresearch.com
4. – https://www.www.bccresearch.com
5. – https://www.www.grandviewresearch.com
6. – https://www.www.mordorintelligence.com
7. – https://www.www.fortunebusinessinsights.com
